F
Francis Barth
Researcher at Sanofi S.A.
Publications - 154
Citations - 8599
Francis Barth is an academic researcher from Sanofi S.A.. The author has contributed to research in topics: Alkyl & Alkoxy group. The author has an hindex of 31, co-authored 153 publications receiving 8342 citations.
Papers
More filters
Journal ArticleDOI
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Allyn C. Howlett,Francis Barth,Tom I. Bonner,Guy A. Cabral,Pierre Casellas,William A. Devane,Christian C. Felder,Miles Herkenham,Ken Mackie,Billy R. Martin,Raphael Mechoulam,Roger G. Pertwee +11 more
TL;DR: It is considered premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification, because pharmacological evidence for the existence of additional types of cannabinoid receptor is emerging and other kinds of supporting evidence are still lacking.
Journal ArticleDOI
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Murielle Rinaldi-Carmona,Francis Barth,Michel Heaulme,David Shire,Bernard Calandra,Christian Congy,Serge Martinez,Jeanne Maruani,Gervais Neliat,Daniel Caput,P. Ferrara,Philippe Soubrie,J. C. Breliere,Gérard Le Fur +13 more
TL;DR: SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor and should prove to be a powerful tool for investigating the in vivo functions of the anandamide/cannabinoid system.
Journal Article
SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor
Murielle Rinaldi-Carmona,Francis Barth,Millan J,Jean-Marie Derocq,P. Casellas,Christian Congy,Didier Oustric,Sarran M,Monsif Bouaboula,Bernard Calandra,Marielle Portier,David Shire,J. C. Breliere,Le Fur Gl +13 more
TL;DR: It is expected that SR 144528 will provide a powerful tool to investigate the in vivo functions of the cannabinoid system in the immune response.
Journal ArticleDOI
A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1 EVIDENCE FOR A NEW MODEL OF RECEPTOR/LIGAND INTERACTIONS
Monsif Bouaboula,Sylvie Perrachon,Laura Milligan,Xavier Canat,Murielle Rinaldi-Carmona,M. Portier,Francis Barth,Bernard Calandra,Florence Pecceu,Johannes Lupker,Jean-Pierre Maffrand,Gérard Le Fur,Pierre Casellas +12 more
TL;DR: Chinese hamster ovary cells transfected with human central cannabinoid receptor (CB1) exhibit high constitutive activity at both levels of mitogen-activated protein kinase (MAPK) and adenylyl cyclase, and the CB1-selective ligand, SR 141716A, that functions as an inverse agonist is proposed as a novel model for receptor/ligand interactions.
Journal ArticleDOI
Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist.
Murielle Rinaldi-Carmona,Francis Barth,Michel Heaulme,R. Alonso,David Shire,Christian Congy,Philippe Soubrie,Jean-Claude Breliere,Gérard Le Fur +8 more
TL;DR: In vitro, SR141716A antagonizes the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and dopamine-stimulated adenylyl cyclase activities in rat brain membranes, and will provide a powerful tool for studying the in vivo functions of the anandamide/cannabinoid system.